Angiotensin Converting Enzyme Inhibitor — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the angiotensin converting enzyme inhibitor class. 14 active patents protecting 2 drugs. First major cliff: 2032. Daily refresh.

2
Drugs in class
14
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators

Azurity 13 patents King Pfizer 1 patents

Cliff calendar — next 15 years

4
32
9
36
1
39

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vasotec
ENALAPRIL MALEATE
 Azurity 13 38 — 2032-11-06
Altace
RAMIPRIL
 King Pfizer 1 75 — 2039-08-16

Most attackable patents

Patent Drug Type Vuln Expiry
12343338 Altace method of use 75 2039-08-16
8778366 Vasotec method of use 55 2032-11-06
9968553 Vasotec method of use 50 2032-11-06
9808442 Vasotec method of use 50 2036-03-25
10154987 Vasotec method of use 50 2036-03-25
11173141 Vasotec formulation 38 2036-03-25
8568747 Vasotec formulation 35 2032-11-06
9855214 Vasotec formulation 30 2032-11-06
10039745 Vasotec formulation 30 2036-03-25
9669008 Vasotec formulation 30 2036-03-25

Strongest defences

Patent Drug Type Vuln Expiry
10772868 Vasotec formulation 30 2036-03-25
9669008 Vasotec formulation 30 2036-03-25
10039745 Vasotec formulation 30 2036-03-25
10786482 Vasotec formulation 30 2036-03-25
11141405 Vasotec formulation 30 2036-03-25
11040023 Vasotec formulation 30 2036-03-25
9855214 Vasotec formulation 30 2032-11-06
8568747 Vasotec formulation 35 2032-11-06
11173141 Vasotec formulation 38 2036-03-25
9808442 Vasotec method of use 50 2036-03-25

Related